Report Highlights
The global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028, at a compound annual growth rate (CAGR) of 14.3% from 2023 through 2028.
Report Includes
- 44 data tables and 45 additional tables
- An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
- Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
- Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
- In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
- Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
- Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
- Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
- A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
- Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
- Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics
Report Scope
The report’s scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.
The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies’ mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.
The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).
Report Synopsis
Report Metrics | Details | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2022 | ||||||||||||||
Forecast period considered | 2023-2028 | ||||||||||||||
Base year market size | $1.7 billion | ||||||||||||||
Market size forecast | $4.3 billion | ||||||||||||||
Growth rate | CAGR of 14.3% from 2023 to 2028 | ||||||||||||||
Units considered | $ Millions | ||||||||||||||
Segments covered | By Technology, Application, and Region | ||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||||||||
Key Market Drivers |
|
||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
- Rising incidence of cancer and hematological malignancies globally.
- Advancements in Next Generation Sequencing (NGS) technology.
- Growing awareness regarding early cancer detection.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Related Reports
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Next-Generation Cancer Diagnostics: Technologies and Global Markets
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Monoclonal Antibodies for Oncology: Global Markets
The global market for monoclonal antibodies in oncology is estimated to grow from $76.2 billion in 2022 to more than $138.1 billion by 2027, with a compound annual growth rate (CAGR) of 12.6% during the forecast period of 2022-2027.
Biological Therapies for Cancer: Technologies and Global Markets
The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
Recent Reports
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More